Fragmin — Competitive Intelligence Brief

Fragmin (BEMIPARIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low Molecular Weight Heparin. Area: Cardiovascular.

discontinued Low Molecular Weight Heparin Factor Xa and thrombin (via antithrombin III enhancement) Cardiovascular Oligosaccharide

Target snapshot

Fragmin (BEMIPARIN) — Pfizer. Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fragmin TARGET	BEMIPARIN	Pfizer	discontinued	Low Molecular Weight Heparin	Factor Xa and thrombin (via antithrombin III enhancement)	1994-01-01
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	marketed	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Fragmin	Dalteparin Sodium	Pfizer Inc.	marketed	Low molecular weight heparin (LMWH)	Factor Xa and thrombin
half amount low molecular weight heparin	half amount low molecular weight heparin	Beijing Anzhen Hospital	marketed	Anticoagulant (low molecular weight heparin)	Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets)
Tinzaparin (Leo)	Tinzaparin (Leo)	Aalborg University Hospital	phase 3	Low molecular weight heparin	Factor Xa, Thrombin
intermediate dose Enoxaparin/ unfractionated heparin	intermediate dose Enoxaparin/ unfractionated heparin	Rajaie Cardiovascular Medical and Research Center	phase 3	Low molecular weight heparin	Antithrombin
UFH	UFH	VarmX B.V.	phase 3	Low molecular weight heparin	Antithrombin III

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low Molecular Weight Heparin class)

1. Pfizer · 1 drug in this class
2. Sanofi · 1 drug in this class